$VTGN
Vistagen Therapeutics, Inc. Stock $vtgn

$vtgn Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000141168524000022 Filed on June 11, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2024
Revenue	$100.0K	$197.3K	$1.064M
YoY Change	-43.69%	12.1%	-568.72%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.567M	$4.120M	$14.06M
YoY Change	53.35%	33.87%	-4.1%
% of Gross Profit
Research & Development	$7.648M	$7.437M	$20.02M
YoY Change	82.22%	-20.35%	-54.88%
% of Gross Profit
Depreciation & Amortization	$34.00K	$32.50K	$127.0K
YoY Change	7.94%	-2.4%	-1.93%
% of Gross Profit
Operating Expenses	$12.22M	$11.56M	$34.09M
YoY Change	70.23%	-6.92%	-42.27%
Operating Profit	-$12.13M		-$33.02M
YoY Change	73.35%		-44.29%
Interest Expense	$1.398M	$1.527M	$3.351M
YoY Change	1338.27%	12116.8%	12690.08%
% of Operating Profit
Other Income/Expense, Net		$312.0K	$312.0K
YoY Change
Pretax Income	-$10.73M	-$9.520M	-$29.36M
YoY Change	55.54%	-22.13%	-50.44%
Income Tax	$0.00	$1.500K	$4.000K
% Of Pretax Income
Net Earnings	-$10.73M	-$9.521M	-$29.36M
YoY Change	55.48%	-22.13%	-50.44%
Net Earnings / Revenue	-10733.0%	-4825.85%	-2759.59%
Basic Earnings Per Share	-$0.35		-$1.52
Diluted Earnings Per Share	-$0.35	-$0.31	-$1.52
COMMON SHARES
Basic Shares Outstanding	27.03M shares	27.03M	19.35M shares
Diluted Shares Outstanding	30.60M shares		19.35M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$108.4M	$119.2M	$119.2M
YoY Change	1026.18%	616.25%	616.25%
Cash & Equivalents	$102.9M	$119.2M	$119.2M
Short-Term Investments	$5.446M	$0.00
Other Short-Term Assets	$2.474M	$1.506M	$1.506M
YoY Change	67.56%	153.07%	153.07%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$110.8M	$120.7M	$120.7M
YoY Change	857.25%	589.26%	589.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$489.0K	$435.0K	$2.255M
YoY Change	2.77%	-14.25%	-18.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$518.0K	$726.0K	$726.0K
YoY Change	-37.13%	-10.83%	-10.83%
Total Long-Term Assets	$2.710M	$2.981M	$2.981M
YoY Change	-21.53%	-16.77%	-16.77%
TOTAL ASSETS
Total Short-Term Assets	$110.8M	$120.7M	$120.7M
Total Long-Term Assets	$2.710M	$2.981M	$2.981M
Total Assets	$113.5M	$123.7M	$123.7M
YoY Change	655.36%	486.33%	486.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.209M	$1.547M	$1.547M
YoY Change	-25.52%	-37.45%	-37.45%
Accrued Expenses	$2.164M	$2.235M	$2.785M
YoY Change	409.54%	183.85%	118.77%
Deferred Revenue	$2.296M	$791.0K
YoY Change	221.43%	10.74%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.236M	$5.123M	$5.123M
YoY Change	54.01%	12.16%	12.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$2.509M	$4.244M	$4.244M
YoY Change	-39.21%	-4.29%	-4.29%
Total Long-Term Liabilities	$2.509M	$4.244M	$4.244M
YoY Change	-39.31%	-4.45%	-4.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.236M	$5.123M	$5.123M
Total Long-Term Liabilities	$2.509M	$4.244M	$4.244M
Total Liabilities	$8.745M	$9.367M	$9.367M
YoY Change	6.86%	3.97%	3.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$366.9M	-$356.2M
YoY Change	9.92%	8.96%
Common Stock	$27.00K	$27.00K
YoY Change	241.77%	269.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$104.8M	$114.3M	$114.3M
YoY Change
Total Liabilities & Shareholders Equity	$113.5M	$123.7M	$123.7M
YoY Change	655.36%	486.33%	486.33%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2024
OPERATING ACTIVITIES
Net Income	-$10.73M	-$9.521M	-$29.36M
YoY Change	55.48%	-22.13%	-50.44%
Depreciation, Depletion And Amortization	$34.00K	$32.50K	$127.0K
YoY Change	7.94%	-2.4%	-1.93%
Cash From Operating Activities	-$10.87M	-$7.197M	-$25.81M
YoY Change	37.74%	-3.69%	-48.08%
INVESTING ACTIVITIES
Capital Expenditures	$42.00K	$28.70K	$61.00K
YoY Change			-71.23%
Acquisitions
YoY Change
Other Investing Activities	-$5.425M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$5.467M	-$28.70K	-$61.00K
YoY Change		-94.57%	-91.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$88.00K	-167.8K	$128.4M
YoY Change	-89.95%	-57.91%	-12419.1%
NET CHANGE
Cash From Operating Activities	-$10.87M	-7.197M	-$25.81M
Cash From Investing Activities	-$5.467M	-28.70K	-$61.00K
Cash From Financing Activities	$88.00K	-167.8K	$128.4M
Net Change In Cash	-$16.25M	-7.394M	$102.5M
YoY Change	131.61%	-11.98%	-299.09%
FREE CASH FLOW
Cash From Operating Activities	-$10.87M	-$7.197M	-$25.81M
Capital Expenditures	$42.00K	$28.70K	$61.00K
Free Cash Flow	-$10.91M	-$7.226M	-$25.87M
YoY Change	38.27%	-3.3%	-48.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001411685
CY2024	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.vistagen.com/20240331#SublicenseAndOtherRevenueMember
CY2023	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.vistagen.com/20240331#SublicenseAndOtherRevenueMember
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0333
CY2023Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0333
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-37761
CY2024	dei	Entity Registrant Name EntityRegistrantName	Vistagen Therapeutics, Inc.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5093315
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	343 Allerton Avenue
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2024	dei	City Area Code CityAreaCode	650
CY2024	dei	Local Phone Number LocalPhoneNumber	577-3600
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024	dei	Trading Symbol TradingSymbol	VTGN
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	62700000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27025209	shares
CY2024	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2024	dei	Auditor Location AuditorLocation	San Francisco, California
CY2024	dei	Auditor Firm AuditorFirmId	100
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119166000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16638000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1432000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	802000	usd
CY2024Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	74000	usd
CY2023Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	67000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	120672000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	17507000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	435000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	507000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1820000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2260000	usd
CY2024Q1	vtgn	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	495000	usd
CY2023Q1	vtgn	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	496000	usd
CY2024Q1	us-gaap	Deferred Costs DeferredCosts	130000	usd
CY2023Q1	us-gaap	Deferred Costs DeferredCosts	218000	usd
CY2024Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	101000	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	101000	usd
CY2024Q1	us-gaap	Assets Assets	123653000	usd
CY2023Q1	us-gaap	Assets Assets	21089000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1547000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2473000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2235000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	796000	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	105000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	791000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	714000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	550000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	486000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5123000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4574000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2674000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2315000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1570000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2120000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	9367000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	9009000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	325000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	325000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27029731	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7315583	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	474441000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	342893000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4522	shares
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4522	shares
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	3968000	usd
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	3968000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-356214000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-326852000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	114286000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	12080000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	123653000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21089000	usd
CY2024	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1064000	usd
CY2023	vtgn	Revenue From Contract With Customer Including Assessed Tax Derecognized RevenueFromContractWithCustomerIncludingAssessedTaxDerecognized	227000	usd
CY2024	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1064000	usd
CY2023	vtgn	Revenue From Contract With Customer Including Assessed Tax Derecognized RevenueFromContractWithCustomerIncludingAssessedTaxDerecognized	227000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20022000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44377000	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14063000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14664000	usd
CY2024	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3351000	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	26000	usd
CY2024	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	312000	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29358000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-59242000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-29362000	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29362000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-59248000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59248000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.52
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.51
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.51
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19354500	shares
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19354500	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6958749	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6958749	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	64716000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3336000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	63000	usd
CY2023	vtgn	Stock Issued During Period Shares Stock Options Exercised For Cash StockIssuedDuringPeriodSharesStockOptionsExercisedForCash	3646	shares
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	104000	usd
CY2023	vtgn	Adjustments To Additional Paid In Capital Warrant Modification AdjustmentsToAdditionalPaidInCapitalWarrantModification	78000	usd
CY2023	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	413670	shares
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3031000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-59248000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	12080000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2182000	usd
CY2024	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	8000	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	35899000	usd
CY2024	vtgn	Stock Issued During Period Shares And Warrants New Issues StockIssuedDuringPeriodSharesAndWarrantsNewIssues	15010810	shares
CY2024	vtgn	Stock Issued During Period Value Shares And Warrants New Issues StockIssuedDuringPeriodValueSharesAndWarrantsNewIssues	93479000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-29362000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	114286000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-29362000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-59248000	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	127000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	130000	usd
CY2024	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-6000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	2182000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3336000	usd
CY2024	vtgn	Expense Related To Asset Acquisition ExpenseRelatedToAssetAcquisition	0	usd
CY2023	vtgn	Expense Related To Asset Acquisition ExpenseRelatedToAssetAcquisition	3559000	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	78000	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	441000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	402000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-250000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3188000	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-495000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-433000	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	516000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	206000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	522000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-934000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25813000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49716000	usd
CY2024	vtgn	Payments To Acquire Laboratory And Other Equipment PaymentsToAcquireLaboratoryAndOtherEquipment	61000	usd
CY2023	vtgn	Payments To Acquire Laboratory And Other Equipment PaymentsToAcquireLaboratoryAndOtherEquipment	212000	usd
CY2024	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	0	usd
CY2023	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	528000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-740000	usd
CY2024	vtgn	Proceeds From Issuance Of Common Stock And Option Exercises Net ProceedsFromIssuanceOfCommonStockAndOptionExercisesNet	0	usd
CY2023	vtgn	Proceeds From Issuance Of Common Stock And Option Exercises Net ProceedsFromIssuanceOfCommonStockAndOptionExercisesNet	104000	usd
CY2024	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	93453000	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	usd
CY2024	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	985000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1034000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	128402000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1041000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	102528000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-51497000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16638000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	68135000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	119166000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16638000	usd
CY2024	vtgn	Insurance Premiums Settled Issuing Note Payable InsurancePremiumsSettledIssuingNotePayable	879000	usd
CY2023	vtgn	Insurance Premiums Settled Issuing Note Payable InsurancePremiumsSettledIssuingNotePayable	1140000	usd
CY2024	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	29000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2024	vtgn	Fair Value Of Common Stock Issued For Asset Acqusition FairValueOfCommonStockIssuedForAssetAcqusition	0	usd
CY2023	vtgn	Fair Value Of Common Stock Issued For Asset Acqusition FairValueOfCommonStockIssuedForAssetAcqusition	3077000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-356200000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119200000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, but are not limited to, those relating to stock-based compensation, revenue recognition, research and development expenses, determination of right-of-use assets under lease transactions and related lease obligations, and the assumptions used to value warrants. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></div>
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">have not experienced any losses in such accounts, and management believes that we are not exposed to significant credit risk due to the nature of the instruments held in the depository institutions.</span></div>
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21420151	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	748230	shares
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1689000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1700000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1254000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1193000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	435000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	507000	usd
CY2016	vtgn	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	1	renewal_option
CY2016Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2016Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	645000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	645000	usd
CY2024	us-gaap	Variable Lease Cost VariableLeaseCost	246000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	207000	usd
CY2024	us-gaap	Lease Cost LeaseCost	891000	usd
CY2023	us-gaap	Lease Cost LeaseCost	852000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	710000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	732000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	753000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	254000	usd
CY2024Q1	vtgn	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2449000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	329000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2120000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	550000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1570000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0854
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0854
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	700000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	900000	usd
CY2024Q1	vtgn	Accrued Expenses For Materials And Contractual Services AccruedExpensesForMaterialsAndContractualServices	482000	usd
CY2023Q1	vtgn	Accrued Expenses For Materials And Contractual Services AccruedExpensesForMaterialsAndContractualServices	412000	usd
CY2024Q1	vtgn	Employee And Non Employee Related Liabilities Current EmployeeAndNonEmployeeRelatedLiabilitiesCurrent	1619000	usd
CY2023Q1	vtgn	Employee And Non Employee Related Liabilities Current EmployeeAndNonEmployeeRelatedLiabilitiesCurrent	337000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	117000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	38000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2235000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	796000	usd
CY2023Q4	vtgn	Warrants Exercisable Percentage Of Common Shares Outstanding Minimum Benchmark WarrantsExercisablePercentageOfCommonSharesOutstandingMinimumBenchmark	0.0999
CY2023Q4	vtgn	Warrants Exercisable Percentage Of Common Shares Outstanding Maximum Benchmark WarrantsExercisablePercentageOfCommonSharesOutstandingMaximumBenchmark	0.1999
CY2023Q4	vtgn	Warrant Percentage Increase Or Decrease Notice Period WarrantPercentageIncreaseOrDecreaseNoticePeriod	P61D
CY2024	vtgn	Class Of Warrant Or Right Warrants Exercised Number ClassOfWarrantOrRightWarrantsExercisedNumber	0	shares
CY2023	vtgn	Class Of Warrant Or Right Warrants Exercised Number ClassOfWarrantOrRightWarrantsExercisedNumber	0	shares
CY2023	vtgn	Class Of Warrant Or Right Expired During Period ClassOfWarrantOrRightExpiredDuringPeriod	263510	shares
CY2023	vtgn	Class Of Warrant Or Right Expired During Period Exercise Price ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice	48.94
CY2024Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P60D
CY2024Q1	vtgn	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	6.24
CY2024Q1	vtgn	Class Of Warrant Or Right Outstanding Warrants Subject To Anti Dilution Protection Feature ClassOfWarrantOrRightOutstandingWarrantsSubjectToAntiDilutionProtectionFeature	0	shares
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	75102420	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1810310	shares
CY2024Q1	vtgn	Common Stock Shares Issuable CommonStockSharesIssuable	222872371	shares
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	702691	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.76
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5000	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	116666	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.62
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3576	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	19.27
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	424	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	84.55
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	815357	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	33.07
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	165000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	609986	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	39.48
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	68000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	815357	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	33.07
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	165000	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2182000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3337000	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.40
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.10
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2300000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3500000	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2100000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0000
CY2024	vtgn	Effective Income Tax Rate Reconciliation Warrant Modifications EffectiveIncomeTaxRateReconciliationWarrantModifications	0.0000
CY2023	vtgn	Effective Income Tax Rate Reconciliation Warrant Modifications EffectiveIncomeTaxRateReconciliationWarrantModifications	0.0003
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0078
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0111
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0050
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0003
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0127
CY2024	vtgn	Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforward EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforward	0.0092
CY2023	vtgn	Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforward EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforward	0.0017
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.1845
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.1857
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0049
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0124
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	46463000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	43603000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3591000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2962000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2986000	usd
CY2024Q1	vtgn	Deferred Tax Assets Operating Lease Right Of Use Assets DeferredTaxAssetsOperatingLeaseRightOfUseAssets	64000	usd
CY2023Q1	vtgn	Deferred Tax Assets Operating Lease Right Of Use Assets DeferredTaxAssetsOperatingLeaseRightOfUseAssets	73000	usd
CY2024Q1	vtgn	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	10188000	usd
CY2023Q1	vtgn	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	8215000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	460000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	643000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	404000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	146000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	60541000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	59256000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	60521000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	59251000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	20000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5000	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	20000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	20000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1300000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10600000	usd
CY2024Q1	vtgn	Deferred Tax Assets Taxable Income Limitation DeferredTaxAssetsTaxableIncomeLimitation	0.80
CY2024	vtgn	Capitalized Research And Development Costs CapitalizedResearchAndDevelopmentCosts	19400000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1283000	usd
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1088000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3648000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	195000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4931000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1283000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001411685-24-000022-index-headers.html	Edgar Link	pending
0001411685-24-000022-index.html	Edgar Link	pending
0001411685-24-000022.txt	Edgar Link	pending
0001411685-24-000022-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vtgn-20230331xexx311.htm	Edgar Link	pending
vtgn-20230331xexx312.htm	Edgar Link	pending
vtgn-20230331xexx321.htm	Edgar Link	pending
vtgn-20230810xexx10163.htm	Edgar Link	pending
vtgn-20231002xexx971.htm	Edgar Link	pending
vtgn-20240331.htm	Edgar Link	pending
vtgn-20240331.xsd	Edgar Link	pending
vtgn-20240331_g1.jpg	Edgar Link	pending
vtgn-exx231x20240611.htm	Edgar Link	pending
vtgn-exx431.htm	Edgar Link	pending
vtgn-20240331_cal.xml	Edgar Link	unprocessable
vtgn-20240331_def.xml	Edgar Link	unprocessable
vtgn-20240331_lab.xml	Edgar Link	unprocessable
vtgn-20240331_pre.xml	Edgar Link	unprocessable
vtgn-20240331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VTGN
Vistagen Therapeutics, Inc. Stock $vtgn

2024 Q2 Form 10-K Financial Statement

#000141168524000022 Filed on June 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VTGN Vistagen Therapeutics, Inc. Stock $vtgn

2024 Q2 Form 10-K Financial Statement

#000141168524000022 Filed on June 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VTGN
Vistagen Therapeutics, Inc. Stock $vtgn